 Delcath Systems Inc NASDAQ: DCTH has announced top-line preliminary results from the Phase 3 FOCUS trial of Hepzato Kit melphalan hydrochloride for injectionhepatic delivery system in patients with liver dominant metastatic ocular melanoma. Based on the preliminary analysis of 87 of enrolled patients, the assessed overall response rate ORR of 29.2 in the Intent to Treat population exceeded the predefined success criteria 21.0 for the primary ORR endpoint. 